Compare Becton Dickinson and Co (BDX) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Remitly Global Inc — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Remitly Global Inc trades at $23.24 (market cap $4.95B). The key difference: Becton Dickinson and Co is far larger — about 8.4× Remitly Global Inc's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Remitly Global Inc pays none. Which is the better fit depends on your goals.
| BDX | RELY | |
|---|---|---|
Market Cap | $41.51B | $4.95B |
Sector | Health | Technology |
52-Week High | $185.39 | $24.28 |
52-Week Low | $135.49 | $12.20 |
Enterprise Value | $57.97B | $4.34B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
RELY trades at $23.68, down 0.38% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates accelerating revenue growth, reaching $1.64B in 2025 with net income turning positive at $67.93M. Recent expansion includes a UAE banking license and Canadian business launch, supporting the 92% analyst buy rating with a $26.75 consensus target.
Outlook remains positive with projected 2026 revenue of $1.7B and net income of $106M. Key opportunities include market share gains in the $800B remittance space, while risks involve competitive pressure from payment giants and execution challenges in international expansion. The stock offers growth potential but requires monitoring of profitability sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
